Get the Stockscreener App
0.1898
1.88%
+0.0035
Pre-market:
.1897
-0.000100
-0.05%
Galera Therapeutics Inc stock is currently priced at $0.1898, with a 24-hour trading volume of 586.61K.
It has seen a +1.88% increased in the last 24 hours and a +14.20% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.1853 pivot point. If it approaches the $0.1977 resistance level, significant changes may occur.
Previous Close:
$0.1863
Open:
$0.1856
24h Volume:
586.61K
Market Cap:
$10.32M
Revenue:
-
Net Income/Loss:
$-69.68M
P/E Ratio:
-0.0879
EPS:
-2.16
Net Cash Flow:
$-48.93M
1W Performance:
+3.89%
1M Performance:
+14.20%
6M Performance:
+110.19%
1Y Performance:
-93.58%
1D Range:
$0.1838
$0.1923
52W Range:
$0.0853
$3.59
Galera Therapeutics Inc Stock (GRTX) Company Profile
Name
Galera Therapeutics Inc
Sector
Industry
Phone
610 725 1500
Address
2 West Liberty Boulevard, Suite 100, Malvern
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-19-21 | Downgrade | BofA Securities | Buy → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Dec-02-19 | Initiated | BTIG Research | Buy |
| Dec-02-19 | Initiated | BofA/Merrill | Buy |
| Dec-02-19 | Initiated | Citigroup | Buy |
| Dec-02-19 | Initiated | Credit Suisse | Neutral |
View All
Galera Therapeutics Inc Stock (GRTX) Latest News
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Benzinga
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
Benzinga
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Benzinga
Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Galera Therapeutics Inc Stock (GRTX) Financials Data
Galera Therapeutics Inc (GRTX) Net Income 2024
GRTX net income (TTM) was -$69.68 million for the quarter ending September 30, 2023, a -10.89% decrease year-over-year.
Galera Therapeutics Inc (GRTX) Cash Flow 2024
GRTX recorded a free cash flow (TTM) of -$48.93 million for the quarter ending September 30, 2023, a -4.09% decrease year-over-year.
Galera Therapeutics Inc (GRTX) Earnings per Share 2024
GRTX earnings per share (TTM) was -$1.89 for the quarter ending September 30, 2023, a +19.92% growth year-over-year.
About Galera Therapeutics Inc
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
3.18%
Cap:
|
Volume (24h):